Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

PeptiCHIP

Financiado

Pre-clinical validation and demonstration of PeptiCHIP: an immunopurification mi...

Pre-clinical validation and demonstration of PeptiCHIP: an immunopurification microfluidic device and software for (neo)antigen identification and prioritization Clinical translation of cancer immunotherapies remains very challenging since 60-80% of patients fail to respond. The challenge stands in identifying specific tumour-fingerprints – the neoantigens - that are peptides expressed uni... ver más

31/03/2025

Valo Therapeutics...

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

VALO THERAPEUTICS OY No se ha especificado una descripción o un objeto social para esta compañía.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-03-13

HORIZON-EIC-2022-TRANSITIONOPEN-01: EIC Transition Open 2022 Expected Impact:At the end of the EIC Transition project, it should be ready for the next stage, whi...

I+D

Cerrada hace 2 años

0% 100% 100%

1 Participantes

Valo Therapeutics Oy

2.23M€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PeptiCHIP PEPTICHIP Streamlined identification of tumour neoantigens... 150K€ Cerrado

MIMIC Molecular mimicry as a key parameter shaping T cell immunity 2M€ Cerrado

nextDART Next generation Detection of Antigen Responsive T cells 1M€ Cerrado

ImmunoChip Nano-assisted digitalizing of cancer phenotyping for immunot... 2M€ Cerrado

NANODIAGNOSTIC Super-resolution microscopy for immune checkpoint inhibitors... 150K€ Cerrado

ReceptorPAINT Imaging Receptomics as a tool for biomedical discovery 2M€ Cerrado

Duración del proyecto: 24 meses Fecha Inicio: 2023-03-13
Fecha Fin: 2025-03-31

Líder del proyecto

VALO THERAPEUTICS OY No se ha especificado una descripción o un objeto social para esta compañía.

Presupuesto del proyecto 2M€

Descripción del proyecto Clinical translation of cancer immunotherapies remains very challenging since 60-80% of patients fail to respond. The challenge stands in identifying specific tumour-fingerprints – the neoantigens - that are peptides expressed uniquely by cancer cells and that are capable of triggering an efficient immune response against cancer. Currently there is no standard method to identify antigens and the few methods available have significant limitations by being quite long, complicated and resource demanding. In response to this clear technological and market gap, Valo Therapeutics (ValoTx, an immunotherapy development company) is introducing PeptiCHIP, i.e. an innovative microfluidic immunopurification device and a peptide prioritisation algorithm to identify the most relevant (neo)antigens to stimulate the immune system and thus increase the chance of success of the immunotherapy. PeptiCHIP can be adapted and used to identify antigens related to any disease. The Proof of Concept (PoC) was successfully demonstrated at University of Helsinki. The IP was protected and ValoTx has full rights to further develop, exploit, and commercialize PeptiCHIP. This EIC Transition project will allow further technology development, testing, validating, and demonstrating it pre-clinically, generating evidence to convince investors and stakeholders, as well as to prepare an extensive and solid transition-to-market plan (T2MP). By being accurate, fast, low-cost, easy to use and working with very small amounts of samples, PeptiCHIP will have great impact in: 1) Research: for discovery & new therapies development since identification of antigens allows the understanding of diseases & immune response mechanisms; 2) Industry: for therapy development & translation into clinical use since the antigens identification & prioritization is a critical step to produce therapies tailored for each patient to ensure responsiveness; 3) Clinic: for patient assessment & immunotherapy tailoring.

Conecta tu I+D

Entra hoy

¿Olvidó su contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores